Osstem Implant, a dental implant company acquired by private equity firm MBK Partners, is facing restructuring controversy after multiple employees reported receiving job reassignment notices. According to investment banking industry sources on the 20th, the company recently eliminated existing roles for some employees and instructed them to find new positions within the organization. Affected employees include a worker four months pregnant and several individuals returning from parental leave. The restructuring follows a workforce reduction last year that cut approximately 20% of staff. The controversy emerges as MBK Partners faces criticism over its management approach at portfolio companies, with employees claiming the firm is pursuing rapid exit strategies that prioritize cost-cutting over employment stability.
Employees Report Job Elimination and Reassignment Pressure
Multiple Osstem Implant employees stated they received notices removing them from existing duties without clear reassignment. Employee A, four months pregnant, said she received notification in May that she would be removed from her assigned work and has remained in standby status without clear instructions. She stated she informed the company of her pregnancy and requested alternative job placement but has not received a concrete assignment.
Employee B, who returned in May after six months of parental leave, said she was removed from her position and has been receiving only training in a task force team. She stated the training consists primarily of production site support, video education, and testing. B claimed she was encouraged to take parental leave during an overseas business reorganization and received task force assignment notification after expressing intent to return.
Employee C, in her seventh year at the company, reported receiving job elimination and standby assignment eight months after returning from parental leave. She stated she is currently assigned to a competitiveness enhancement task force receiving simple packaging work training at a production facility. Employee D, who received no work assignments for one month after parental leave return, stated bonuses were eliminated after the company acquisition and company atmosphere changed significantly.
The employees claim the company reduced 500 to 600 positions out of 2,800 employees last year, representing approximately 20% of the workforce. They assert MBK is pursuing aggressive management similar to its approach at Homeplus to achieve rapid exit.
Osstem Implant Confirms Job Reassignment Training Program
Osstem Implant acknowledged restructuring is underway, stating job reassignment training is being conducted for some employees requiring job transitions due to business direction reorganization. The company disputed the claim that hundreds of employees left last year, stating only about 10 employees departed. The company stated it is implementing protection procedures in compliance with law for pregnant workers and parental leave returnees.
MBK Partners stated MBK is only a shareholder of Osstem Implant, not an owner, and the matter is a management decision by company executives. The firm indicated it has no direct involvement in the restructuring decisions.
Operating Profit Declined 50% Following MBK Acquisition
Osstem Implant, South Korea's number one dental implant company, was acquired in 2023 when the MBK-UCK consortium secured a 96.1% stake for approximately 2.5 trillion won. The company's consolidated operating profit last year was 80 billion won, half the previous year's 160 billion won.
Despite the profit decline, the company paid 110.1 billion won in dividends for 2024 results last year and 39.2 billion won in March this year. These amounts represent significant increases compared to pre-acquisition dividends of 8.6 billion won in 2021 and 3.2 billion won in 2022.
Industry Experts Cite Cost Reduction Pressure from Acquisition Financing
Investment banking industry sources interpret the current controversy as connected to cost reduction efforts amid deteriorating performance and acquisition financing covenant management pressure. The sharp operating profit decline has increased pressure to meet covenant standards through cost reduction, potentially leading to aggressive workforce efficiency measures.
Professor Lee Jung-hwan of Hanyang University's Department of Economics and Finance stated that while private equity funds themselves are not problematic, cost efficiency pressure inevitably increases when profitability targets are tied to acquisition financing. He stated workforce and profitability management are two sides of the same coin, emphasizing the importance of balance with employment stability.
FAQ
What restructuring measures is Osstem Implant implementing?
Osstem Implant is conducting job reassignment training for employees whose existing roles were eliminated, requiring them to find new positions within the organization. The company stated this is part of business direction reorganization affecting some employees requiring job transitions.
How did Osstem Implant's financial performance change after the MBK acquisition?
Osstem Implant's consolidated operating profit declined from 160 billion won to 80 billion won last year, a 50% reduction. However, dividend payments increased significantly, with 110.1 billion won paid for 2024 results and 39.2 billion won in March this year, compared to 8.6 billion won in 2021 and 3.2 billion won in 2022 before the acquisition.
What is MBK Partners' position on the restructuring controversy?
MBK Partners stated it is only a shareholder of Osstem Implant, not an owner, and the restructuring is a management decision by company executives. The firm indicated it has no direct involvement in the personnel decisions being contested by employees.
